BeiGene
BGNE
#982
Rank
ยฃ15.94 B
Marketcap
ยฃ145.78
Share price
0.49%
Change (1 day)
22.17%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -ยฃ0.69 Billion

According to BeiGene 's latest financial reports the company's current earnings are ยฃ3.31 Billion. In 2023 the company made an earning of -ยฃ0.96 Billion, an increase over its 2022 earnings that were of -ยฃ1.42 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -ยฃ0.69 Billion-28.37%
2023 -ยฃ0.96 Billion-32.52%
2022 -ยฃ1.42 Billion24.39%
2021 -ยฃ1.14 Billion-13.21%
2020 -ยฃ1.31 Billion72.69%
2019 -ยฃ0.76 Billion36.01%
2018 -ยฃ0.56 Billion616.83%
2017 -ยฃ77.71 Million-15.24%
2016 -ยฃ91.69 Million107.91%
2015 -ยฃ44.1 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-ยฃ14.33 Million-97.92%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ93.01 Million-86.49%๐Ÿ‡บ๐Ÿ‡ธ USA